Back

Benefits and risks of longer-than-1-year dual antiplatelet therapy in TWLIGHT-like patients with high risk of ischemic or bleeding events after drug-eluting stents implantation

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Interventions in Coronary Artery Disease Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

4 More presentations in this session

Presentation thumbnail
Managed care improves prognosis in acute myocardial infarction survivors. Data from the MAnaged Care for Acute Myocardial Infarction Survivors (MACAMIS) Programme.
Professor P. Jankowski (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Systematic review and meta-analysis of placebo-controlled invasive interventions for the management of chronic stable angina
Doctor M. Rivera (St Louis, US)
Abstract Slides
Presentation thumbnail
Quantitative flow ratio to predict non-target-vessel-related events at 5 years in STEMI patients undergoing angiography-guided revascularization
Doctor S. Bar (Bern, CH)
Abstract Slides
Presentation thumbnail
Risk stratification based on academic research consortium high bleeding risk criteria for long-term bleeding event after everolimus-eluting stent implantation
Doctor K. Miura (Kurashiki, JP)
Abstract Slides

Access the full session

Session thumbnail
Interventions in Coronary Artery Disease

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources